Riskpilot← Back to searchSign inGet full accessPHARMA-SKAN ApS
APSActiveCVR 16275247Adelgade 27Manufacture of pharmaceutical preparations · NACE 2120Est. 199218 employees
Revenue 2025
DKK 12,3M
-19% vs 2024
EBITDA margin
82.2%
-29% vs 2024
Equity ratio
51.0%
Financial strength
Net profit 2025
DKK 7,9M
-30% vs 2024
| Revenue | DKK 12,3M | -19% |
| EBITDA | DKK 10,1M | -29% |
| Net profit | DKK 7,9M | -30% |
| Total assets | DKK 16,8M | -28% |
| Equity | DKK 8,5M | -55% |
| Employees | 18 | — |
Legal name
PHARMA-SKAN ApS
CVR number
16275247
Legal form
Anpartsselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
1. juli 1992
Share capital
DKK 200.000
Employees
18 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør i forening med
bestyrelsesformanden eller af den samlede bestyrelse i forening
Company purpose
Selskabets formål er at drive egen samt kontraktproduktion, handel og distribution af lægemidler, medicinske produkter samt andre beslægtede produkter. Selskabet udfører desuden udviklingsrelaterede ydelser for tredjepart samt anden hermed forbundet virksomhed
Address
Adelgade 27
Phone
+4587939090
Email
info@pharma-skan.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11.586 | 11.365 | 11.464 | 14.995 | 13.237 | 14.246 | 10.083 | 9.935 | 12.585 | 12.420 | 14.800 | 15.308 | 15.272 | 12.340 |
| Staff expenses | -6.474 | -5.106 | -5.742 | -6.184 | -6.793 | -7.151 | -6.991 | -6.898 | -7.159 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | 11.196 | 10.957 | 11.016 | 14.635 | 12.785 | 13.784 | 9.546 | 9.274 | 11.952 | 11.723 | 13.964 | 14.565 | 14.201 | 10.142 |
| Depreciation & amort. | -58 | -20 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 11.138 | 10.936 | 11.016 | 14.635 | 12.785 | 13.784 | 9.546 | 9.274 | 11.952 | 11.723 | 13.964 | 14.565 | 14.201 | 10.142 |
| Net financials | -2 | -2 | -1 | -2 | -6 | -7 | -11 | -25 | -93 | -95 | -18 | 177 | 273 | -46 |
| Profit before tax | 11.136 | 10.935 | 11.015 | 14.634 | 12.779 | 13.777 | 9.535 | 9.249 | 11.859 | 11.627 | 13.945 | 14.742 | 14.474 | 10.096 |
| Tax | 2.784 | 2.734 | 2.698 | 3.433 | 2.811 | 3.031 | 2.097 | 2.035 | 2.609 | 2.558 | 3.068 | 3.244 | 3.186 | 2.221 |
| Net profit | 8.352 | 8.200 | 8.316 | 11.201 | 9.968 | 10.745 | 7.438 | 7.214 | 9.250 | 9.069 | 10.877 | 11.498 | 11.288 | 7.875 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 34.872 | 36.916 | 40.108 | 45.149 | 41.575 | 38.215 | 18.214 | 18.877 | 23.592 | 21.112 | 23.501 | 23.561 | 23.310 | 16.759 |
| Equity | 17.603 | 15.803 | 14.119 | 15.320 | 15.288 | 16.033 | 13.471 | 14.685 | 17.935 | 17.004 | 18.881 | 19.880 | 19.168 | 8.543 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 234 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 17.269 | 21.113 | 25.967 | 29.742 | 26.255 | 22.019 | 4.641 | 3.854 | 5.531 | 3.925 | 4.480 | 3.507 | 3.899 | 7.944 |
| Total debt | 17.269 | 21.113 | 25.967 | 29.742 | 26.255 | 22.019 | 4.641 | 4.088 | 5.531 | 3.925 | 4.480 | 3.507 | 3.899 | 7.944 |
EBITDA margin
82.2%
This company
15.8%
Market median
+420% vs market
20122025
Equity ratio
51.0%
This company
38.2%
Market median
+34% vs market
20122025
Return on equity
92.2%
This company
18.4%
Market median
+401% vs market
20122025
Net profit margin
63.8%
This company
8.1%
Market median
+688% vs market
20122025
Asset turnover
0.74×
This company
1.12×
Market median
-34% vs market
20122025
Debt / equity
0.96×
This company
0.62×
Market median
+55% vs market
20122025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
BP Management | Management | 1999 | — | — |
ET | Audit | 1992 | — | — |
SR Management | Management | 2017 | — | — |
AR Management | Management | 1992 | — | — |
JR Management | Management | 1992 | — | — |
IG Management | Management | 2025 | — | — |
LW Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
PE Management | Management | 1992 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JD | Chairman | 2025 | — | — |
| Board of Directors | 2025 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
BESULA ApS | Company | 100.0% | 100.0% | 2006 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
JDA-Invest ApS
PHARMA-SKAN ApS Board members of PHARMA-SKAN ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Berit Pia Rasmussen | Management | 0 companies |
| Erik Tronborg Andersen | Audit | 0 companies |
| Susanne Rasmussen | Management | 0 companies |
| Aage Rasmussen | Management | 0 companies |
| Judy Rasmussen | Management | 0 companies |
| Ib Gunnar Christensen | Management | 0 companies |
| Line Wulff | Chief Executive Officer | 0 companies |
| Per Emil Hasselbalch Stakemann | Management | 0 companies |
| Jan Dam | Chairman | 0 companies |
| Kent Ernst Hansen | Board of Directors | 0 companies |